Levothyroxine vs Liothyronine: T4 vs T3 Thyroid Medications

T4 vs T3: What Is the Difference?

The thyroid gland produces two hormones: thyroxine (T4) and triiodothyronine (T3). T4 is the predominant hormone produced by the thyroid (about 80% of output), but T3 is the biologically active form — it binds to thyroid hormone receptors in cells and drives metabolic effects. Most T3 in the body comes from peripheral conversion of T4 to T3 by deiodinase enzymes in tissues.

Levothyroxine is synthetic T4. Liothyronine (brand name: Cytomel) is synthetic T3. Most guidelines recommend levothyroxine monotherapy as the standard treatment for hypothyroidism, but a subset of patients continue to have symptoms despite normal TSH levels on levothyroxine alone.

Side-by-Side Comparison

Why Most Patients Do Well on Levothyroxine Alone

For most patients with hypothyroidism, levothyroxine monotherapy is sufficient. The peripheral conversion of T4 to T3 is efficient enough that serum T3 levels normalize when TSH is in the target range. Large randomized trials comparing T4 monotherapy to T4+T3 combination therapy have generally not shown a benefit of combination therapy in unselected hypothyroid patients.

The Case for Combination T4+T3 Therapy

Despite normal TSH levels, approximately 10–15% of patients on levothyroxine continue to report symptoms of hypothyroidism — fatigue, brain fog, weight gain, depression. Several mechanisms may explain this:

1. Impaired T4-to-T3 conversion — Genetic variants in deiodinase enzymes (particularly DIO2) may reduce peripheral T4-to-T3 conversion in some patients, leading to relative T3 deficiency despite normal T4 and TSH levels.
2. Tissue-specific T3 deficiency — Even with normal serum T3, some tissues may not receive adequate T3 if local conversion is impaired.
3. Loss of pulsatile T3 secretion — The healthy thyroid secretes both T4 and T3. Levothyroxine monotherapy does not replicate the T3 component of normal thyroid secretion.

Evidence for Combination Therapy

The evidence for T4+T3 combination therapy is mixed. A landmark 1999 study by Bunevicius et al. (NEJM) found that replacing 50 mcg of T4 with 12.5 mcg of T3 improved mood and neuropsychological function in hypothyroid patients. However, subsequent larger trials have not consistently replicated these findings.

A 2019 systematic review of 14 randomized trials found no significant difference in quality of life, symptoms, or cognitive function between T4 monotherapy and T4+T3 combination therapy in the overall population. However, subgroup analyses suggest patients with the DIO2 polymorphism may preferentially benefit from combination therapy.

Who Might Benefit From Adding T3?

The American Thyroid Association's 2014 guidelines state that combination T4+T3 therapy may be considered in a select subset of patients who:

• Continue to have hypothyroid symptoms despite TSH in the normal range on levothyroxine
• Have had a total thyroidectomy (no residual thyroid to produce any T3)
• Have a DIO2 polymorphism (pharmacogenomic testing available)
• Prefer combination therapy after informed discussion of risks and benefits

Practical Challenges With Liothyronine

Liothyronine's short half-life (~24 hours) means it must be taken 2–3 times daily to maintain stable blood levels. Peak T3 levels after a dose can cause palpitations, anxiety, and other hyperthyroid symptoms. Sustained-release T3 formulations are in development but not yet widely available.

Monitoring is also more complex: TSH is less reliable as a monitoring parameter when T3 is added, and free T3 levels must be checked. The risk of iatrogenic hyperthyroidism — with its associated risks of atrial fibrillation and bone loss — is higher with combination therapy.

Desiccated Thyroid Extract (Armour Thyroid)

Desiccated thyroid extract (DTE), derived from porcine thyroid glands, contains both T4 and T3 in a fixed 4:1 ratio. Some patients prefer DTE because it more closely mimics natural thyroid secretion. However, the T4:T3 ratio in DTE (4:1) differs from human thyroid secretion (approximately 14:1 T4:T3), meaning DTE delivers relatively more T3 than the human thyroid does.

DTE is a reasonable option for patients who prefer it and who are informed about its limitations. It is not recommended as first-line therapy by major guidelines but is an acceptable alternative for patients who do not respond adequately to levothyroxine alone.

The Bottom Line

Levothyroxine monotherapy remains the standard of care for hypothyroidism and is appropriate for the vast majority of patients. For the subset of patients with persistent symptoms despite optimal levothyroxine therapy, a trial of combination T4+T3 therapy is a reasonable option after thorough discussion of the evidence, risks, and practical challenges. This decision should be made collaboratively with an endocrinologist.

For more information, see our complete levothyroxine guide and levothyroxine drug monograph.

References

1. Bunevicius R, et al. Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl J Med. 1999;340(6):424-429.
2. Idrees T, et al. Combination T4 and T3 therapy for hypothyroidism: a systematic review and meta-analysis. Thyroid. 2020;30(8):1154-1167.
3. Jonklaas J, et al. Guidelines for the treatment of hypothyroidism. Thyroid. 2014;24(12):1670-1751.